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Abstract: Improved molecular understanding of breast cancer in recent years has led to the 
discovery of important drug targets such as HER-2 and EGFR. Lapatinib is a potent dual inhibi-
tor of HER-2 and EGFR. Preclinical and phase I studies have shown activity with lapatinib in a 
number of cancers, including breast cancer, and the drug is well tolerated. The main known drug 
interactions are with paclitaxel and irinotecan. The most signiﬁ  cant side-effects of lapatinib are 
diarrhea and adverse skin events. Rates of cardiotoxicity compare favorably with trastuzumab, a 
monoclonal antibody against HER-2. This paper focuses on lapatinib in advanced and metastatic 
breast cancer, which remains an important therapeutic challenge. Phase II and III studies show 
activity as monotherapy, and in combination with chemotherapy or hormonal agents. Results 
from these studies suggest that the main beneﬁ  t from lapatinib is in the HER-2 positive breast 
cancer population. Combinations of lapatinib and trastuzumab are also being studied and show 
encouraging results, particularly in trastuzumab-refractory metastatic breast cancer. Lapatinib 
may have a speciﬁ  c role in treating HER-2 positive CNS metastases. The role of lapatinib as 
neoadjuvant therapy and in early breast cancer is also being evaluated.
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Management issues in treatment of locally 
advanced and metastatic breast cancer
The molecular revolution in oncology is having a major impact on the pharmacotherapy 
of breast cancer, a disease which has long been recognized as the most drug-sensitive 
of the common adult solid tumors. The majority of patients whose tumors express 
steroid hormone receptors will respond for variable periods of time to endocrine therapy 
with varying degrees of clinical beneﬁ  t. For those whose tumors lack such receptors, 
and in the case of receptor positive cancers that become resistant to endocrine agents, 
conventional cytotoxic chemotherapy produces frequent responses.
These responses frequently palliate the distressing symptoms of cancer, and 
provide a meaningful degree of survival prolongation. The overwhelming majority 
of these responses end in relapse, however, and cure remains essentially anecdotal. 
Chemotherapy and endocrine therapy produce a greater impact when they are given 
to patients with earlier stage disease as “adjuvants” to deﬁ  nitive loco-regional therapy 
(surgery and or radiotherapy). “Neoadjuvant” or “induction” therapy refers to the strat-
egy of administering systemic treatments to patients prior to deﬁ  nitive loco-regional 
therapy. Induction therapy can render inoperable tumors resectable, and can increase 
the prospects for breast conservation. There are also theoretical advantages to the early 
initiation of systemic therapy in these patients, eg, the delivery of drugs through intact 
vasculature, in vivo assessment of response to drugs, and the opportunity to study the 
biological effects of treatment.
Chemotherapy is, however, a very non-speciﬁ  c treatment, which is injurious to 
normal as well as malignant tissues, producing clinical toxicity, which can be severe. OncoTargets and Therapy 2008:1 22
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In addition, most chemotherapeutic agents were developed 
empirically, often in advance of an understanding of their 
mechanisms of action.
Recent years have seen an improved molecular under-
standing of breast cancer biology, an understanding which 
has ushered in an era of speciﬁ  c molecular therapeutics for 
breast cancer. One of the most intensively studied systems, 
and one which has already proven vulnerable to pharmaco-
therapy, is the human epidermal growth factor system.
The epidermal growth factor 
receptor system in breast cancer
The c-erbB or HER (human epidermal growth factor 
receptor) family of transmembrane tyrosine kinases consists 
of four known members (epidermal growth factor receptor 
(EGFR), HER-2, HER-3, and HER-4). These receptors consist 
of an extracellular domain, a transmembrane region, and an 
intracellular domain with tyrosine kinase function except 
HER-3 which lacks kinase activity. When a ligand binds to a 
receptor, the receptor forms homo- or hetero-dimers, which 
leads to the activation of tyrosine residues in the intracellular 
domain. There are numerous Erb ligands, including epider-
mal growth factor (EGF), TGF-α, epiregulin, amphiregulin, 
and neuregulins. However, HER-2 has no known ligand, 
and appears to mediate its effects through dimerization with 
other members of the HER family. Important downstream 
proteins activated by these pathways include the PI3K-Akt 
and the RAF–MEK–MAPK pathways, which have key roles 
in cell proliferation and survival (reviewed in [Yarden and 
Sliwkowski 2001]).
The HER-2 gene is over-expressed and/or ampliﬁ  ed in 
approximately 20%–30% of invasive breast cancers and 
is associated with more aggressive tumor behavior and 
decreased overall survival (Slamon et al 1987). A review of 
40 different studies, which included 5,232 patients, reported 
that on average 45% of breast cancers were positive for EGFR 
(range 14%–91%) (Klijn et al 1992). The range of positivity 
reported may relate to different methods of detecting EGFR. 
EGFR expression has been associated with poorer prognosis 
in breast cancer (Sainsbury et al 1987; Toi et al 1994).
Trastuzumab, a monoclonal antibody against HER-2 was 
the ﬁ  rst targeted therapy available in HER-2 over-expressing 
breast cancer, and has become ﬁ  rst-line treatment in both 
early and advanced disease (Engel and Kaklamani 2007). 
Trastuzumab acts by binding to the extracellular domain 
of HER-2 and also mediates antibody-dependent cellular 
cytoxicity (ADCC) (Cooley et al 1999). Trastuzumab 
enhances response to chemotherapy and has signiﬁ  cantly 
improved outcomes in this subgroup of patients. However, 
not all patients with HER-2 over-expressing breast cancers 
respond to trastuzumab therapy. In the metastatic setting, 
the response rate to trastuzumab monotherapy is less than 
35% (Vogel et al 2002), and most patients who respond 
initially develop resistance within two years (Nahta and 
Esteva 2007). Trastuzumab therapy has also been associ-
ated with signiﬁ  cant rates of cardiomyopathy, in particular 
when administered in combination with anthracyclines, or 
to patients with prior anthracycline exposure. The incidence 
of brain metastases in patients with HER-2 positive disease 
increases on trastuzumab treatment, possibly reflecting 
improved extra-cerebral disease control with this agent 
which does not cross the blood–brain barrier (BBB) (Clayton 
et al 2004).
A number of EGFR inhibitors are also licensed for use 
in clinical oncology. These include the small molecule 
tyrosine kinase inhibitors geﬁ  tinib (Baselga and Averbuch 
2000) and erlotinib (Pollack et al 1999), and the monoclonal 
antibody cetuximab (Goldstein et al 1995). However, to 
date, clinical trials with EGFR inhibitors have yielded disap-
pointing results in breast cancer therapy. Geﬁ  tinib mono-
therapy in metastatic breast cancer showed response rates of 
2%–13% (von Minckwitz et al 2005). Erlotinib and cetuximab 
have been studied in combination with chemotherapy in 
advanced breast cancer. Reports from trials to date have not 
shown any enhanced beneﬁ  t with addition of EGFR inhibitors 
to chemotherapy. However, a number of trials with these agents 
are ongoing, and may have therapeutic beneﬁ  ts in speciﬁ  c 
subgroups of breast cancer, such as triple negative disease.
Lapatinib is a dual inhibitor of HER-2 and EGFR. It has 
shown promising results in clinical trials in breast cancer 
and is now approved for the treatment of trastuzumab-
refractory HER-2 positive metastatic breast cancer. This 
review focuses on the use of lapatinib in advanced and 
metastatic breast cancer.
Lapatinib: pharmacology, mode 
of action and pharmacokinetics
Pharmacology and mode of action
Lapatinib (GW572016, Tykerb®/Tyverb®) is an orally 
bio-available 6-thiazolylquinazoline which is a potent dual 
inhibitor of EGFR and HER-2 (Gaul et al 2003). Lapatinib 
binds to the adenosine triphosphate (ATP) binding site of 
both EGFR and HER-2. Lapatinib binds to the inactive form 
of EGFR and has a slower dissociation rate than selective 
EGFR inhibitors, such as erlotinib, which binds to the active 
form of EGFR. The estimated dissociation constants (Ki
app) of OncoTargets and Therapy 2008:1 23
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lapatinib for EGFR and HER-2 are 3.0  ±  0.2 nM and 13  ±  1 nM 
respectively (Wood et al 2004). Lapatinib inhibits puriﬁ  ed 
EGFR and HER-2 with a 300-fold selectivity in comparison 
to other kinases, and with IC50 values 12 nM (Table 1) 
(Rusnak et al 2001).
Preclinical models have shown that tumor cell lines 
(derived from a number of different tumor types including 
breast, head and neck, vulva, lung, and gastric) which 
over-express either EGFR or HER-2 are more sensitive 
to lapatinib. Rusnak et al (2007) described a model for 
determining lapatinib sensitivity in cell lines. Using a panel 
of human normal and tumor cell lines (including breast, 
colon, gastric, head and neck, lung, ovarian, and pancreatic 
cancer cell lines), IC50 values ranged from 0.025 μM to 
11.5 μM (breast tumors range 0.025–7.01 μM). Cell line 
sensitivity correlated with receptor function, particularly 
HER-2, although cell lines with increased EGFR expres-
sion and modest HER-2 expression also showed sensitivity. 
Simultaneous consideration of both receptors was found to 
be the best predictor of response.
Lapatinib binding of EGFR and HER-2 has been shown 
to decrease EGFR, HER-2, Raf, AKT, and MAPK activity 
(Xia et al 2002; Konecny et al 2006; Zhou et al 2006; Nahta 
et al 2007). MAPK and AKT may be important biomarkers 
of response to lapatinib. MAPK is involved in proliferation, 
and AKT is a key pathway in cell survival (Xia et al 2002). 
Xia et al (2002) reported that lapatinib markedly decreases 
phosphorylation of MAPK and AKT in the HER-2 over-
expressing BT474 breast cancer cell line, and in human tumor 
xenografts. In vitro, this corresponded with a 23-fold increase 
in apoptosis. Using gene expression proﬁ  les, Hegde et al 
(2007) have shown that lapatinib treatment results in strong 
differential regulation of genes in the Akt pathway in sensi-
tive breast cancer cell lines, compared with less sensitive cell 
lines (Hegde et al 2007). These include genes involved in cell 
cycle control and cellular metabolic processes. In particular, 
lapatinib up-regulates the pro-apoptotic gene FoxO3A in the 
sensitive breast cancer cell lines BT474 and SKBR3.
Gene expression proﬁ  ling also showed that lapatinib 
treatment stimulated hormone receptor expression in cell 
lines with moderate estrogen and progesterone levels (Hegde 
et al 2007). Interestingly, lapatinib has been shown to restore 
tamoxifen sensitivity in a resistant breast cancer cell line, 
via inhibition of estrogen-stimulated transcriptional activity 
(Chu et al 2005). Thus, lapatinib may sensitize hormone 
resistant tumors to hormonal agents.
Pharmacokinetics
In six healthy volunteers, administered a single oral dose 
of 250 mg lapatinib, the predominant route of excre-
tion of lapatinib and its metabolites was feces (median 
92%, range 60%–98%). Approximately 20% of the drug 
was excreted un-metabolized. Less than 2% excretion was 
urinary (EGF10019) (GlaxoSmithKline). Pharmacokinetic 
studies of single and multiple doses of lapatinib in healthy 
subjects have shown a lag in detecting serum levels of drug 
post ingestion, suggesting a delay in oral absorption. Peak 
serum concentrations occur at a median of three hours 
(range 1.5–6 hours) (Bence et al 2005). Lapatinib solubility 
is pH dependent, and decreases with increasing pH. This 
suggests that absorption may decrease as the drug passes 
through the gastro-intestinal (GI) tract (Bence et al 2005). 
It is recommended that lapatinib should be taken at least 
1 hour before or after a meal. In general, increasing dose 
led to increasing serum levels. A drug half-life of 24 hours 
has been suggested, which lends itself to a once-daily dosing 
regime (Bence et al 2005).
Lapatinib exhibited a similar pharmacokinetic proﬁ  le in 
heavily pretreated metastatic cancer patients. In the phase 
I study EGF10004, Burris et al (2005) reported that peak 
serum concentrations were achieved at 3 to 6 hours. In 
general, increased dose led to increased serum concentration. 
The best dose-response activity with lapatinib was found at 
1200 mg once daily, while doses from 500 to 1600 mg once 
daily were well tolerated. Trough serum levels in patients 
with tumor response to drug ranged from 0.3 to 0.6 μg/mL 
(Burris et al 2005). Of note, animal studies have suggested 
drug penetration of tumors can be up to ﬁ  ve times that of 
serum (Clark et al 2002).
Potential drug interactions
Lapatinib undergoes metabolism by cytochrome P450 
isoenzymes. In vitro studies indicate that lapatinib is 
metabolized predominantly by CYP3A4 and CYP3A5, and 
to lesser extent by CYP2C19 (Herendeen et al 2004; Smith 
et al 2004). Healthy volunteers given the CYP3A4 inhibitor 
Table 1 Kinase inhibition by lapatinib (GW572016) (adapted from Rusnak 
et al 2001)
Kinase IC50 with lapatinib (nM)
EGFR 10.8 ± 0.53
HER2 9.2 ± 0.75
HER4 367 ± 4.2
c-src 3500 ± 650
c-RAF, MEK, ERK, VEGFR-2 all 10,000OncoTargets and Therapy 2008:1 24
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ketoconozole for 7 days (EGF10013) showed an increase 
in serum plasma concentration and the elimination half life 
of lapatinib (Smith et al 2004). Volunteers administered 
the CYP3A4 inducer carbamazepine (EGF10018) showed 
decreased lapatinib serum concentrations (Herendeen et al 
2004). These data suggest the important role of CYP3A 
enzymes as one of the main pathways of lapatinib metabolism 
in vivo. As a result, co-prescribing of any drugs which inhibit 
or induce CYP3A should be considered carefully.
In the pharmacokinetic analysis of the phase I study 
combining lapatinib and paclitaxel (EGF10009), paclitaxel 
increased the area under the plasma concentration-time 
curve (AUC) of lapatinib by a factor of 1.2 (1.0–1.4), and 
the maximum plasma concentration (Cmax) by 1.4 (1.1–1.7) 
(Jones et al 2004, GlaxoSmithKline). The AUC of paclitaxel 
was increased by 1.2 (1.1–1.4) by the combination. Paclitaxel 
had been reported as a CYP3A4 substrate (Beulz-Riche 
et al 2002). These pharmacokinetic data suggest that pacli-
taxel may act as an inhibitor of CYP3A4.
There was also a signiﬁ  cant drug interaction between 
lapatinib and SN-38, the active metabolite of irinotecan, 
in a phase I study of lapatinib and FOLFIRI chemotherapy 
(EGF10011) (Midgley et al 2007). The AUC for SN-38 
increased by 41% and Cmax increased by 32%. No signiﬁ  -
cant pharmacokinetic interactions have been found between 
lapatinib and capecitabine (Chu et al 2007), trastuzumab 
(Storniolo et al 2008), letrozole (GlaxoSmithKline), 
oxaliplatin and 5-FU (Siegel-Lakhai et al 2007), or docetaxel 
(GlaxoSmithKline).
Membrane-bound drug transporters (eg, ABC efﬂ  ux 
transporters P-gp and BCRP) play an important role in 
the transport of many substrates both into and out of cells, 
and play a role in tumor resistance to many traditional 
chemotherapy drugs (O’Connor et al 2007). At physiological 
levels, lapatinib has been shown to be a both a substrate and 
an inhibitor of P-gp and BCRP, and an inhibitor of hepatic 
uptake transporter OATP 1B1 (Polli et al 2008). Interest-
ingly, efﬂ  ux pumps in the BBB appear to account for low 
central nervous system (CNS) lapatinib concentrations in 
health. However, promising responses of brain metastases in 
clinical studies have led to the suggestion that there may be 
disruption of efﬂ  ux pumps in disease (Polli et al 2008).
Safety and tolerability of lapatinib
The safety and side-effect proﬁ  le of lapatinib has been exten-
sively monitored (Table 2). The most common toxicities asso-
ciated with lapatinib use are diarrhea and rash. The potential 
cardiac toxicity of HER-2 inhibition has also been monitored.
Diarrhea
Diarrhea is the most commonly reported adverse event in 
clinical trials with lapatinib. Gastro-intestinal disturbance 
is a recognized side-effect of EGFR inhibitors. A pooled 
analysis of diarrhea events in patients treated with lapatinib 
(1000–1500 mg/day) in 11 completed clinical trials in 
a variety of solid tumors (phase I/II/III; n = 2093) has 
recently been published (Crown et al 2008). The drug was 
administered as monotherapy (n = 926) or in combination 
with capecitabine (n = 198) or taxanes (n = 687). Overall, 
diarrhea was reported in 55% of patients treated with 
lapatinib, compared to 24% of those not receiving the drug. 
Diarrhea occurred more frequently in those treated with 
lapatinib and capecitabine (65%), compared with 51% of 
patients receiving lapatinib as monotherapy, and 48% in those 
receiving lapatinib and a taxane. Most events were grade 1/2. 
Grade 3 diarrhea occurred in less than 10% of cases, and 
grade 4 events were rare (1%). However, fatalities from 
septic shock have been reported in this setting.
The mechanism of GI upset related to EGFR inhibition 
has not been fully elucidated, and the side-effect proﬁ  le of 
diarrhea with lapatinib use is similar to that reported with 
other EGFR inhibitors. However, it has been noted from 
pharmacokinetic studies that the frequency of diarrhea was 
dose-related, and not related to serum levels of the drug, 
suggesting a direct local action on the epithelium of the 
GI tract as a possible mechanism of action (Burris et al 2005; 
Crown et al 2008).
In general, lapatinib-related diarrheal events were mild to 
moderate, of early onset, and of short duration. The recom-
mended practical management of diarrhea is not evidence 
based, but includes accepted steps similar to management of 
this condition when induced by other drugs (Moy and Goss 
2007). Improved understanding of the side-effect potential 
of lapatinib and early introduction of pro-active measures in 
clinical studies to reduce this complication have decreased 
the frequency and severity of GI disturbances.
Cardiac toxicity
Cardiac toxicity has emerged as one the main adverse events 
associated with trastuzumab treatment. In the metastatic 
breast cancer setting, trastuzumab treatment is associated 
with approximately 10% grade 3 cardiac toxicity (Slamon 
et al 2001). Anthracyclines (which are also cardiotoxic) in 
combination with trastuzumab result in increased cardiotox-
icity. As a result, concomitant administration of trastuzumab 
with anthracyclines is generally not recommended outside 
clinical trials. It has been noted that trastuzumab-related heart OncoTargets and Therapy 2008:1 25
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failure tends to improve with discontinuation of treatment 
(Ewer et al 2005; Guarneri et al 2006). In contrast, the rate 
of cardiac toxicity with lapatinib seems to be much lower. 
No signiﬁ  cant cardiac toxicity was reported in the phase 
I pharmacokinetic study EGF10004 (Burris et al 2005). 
Perez et al (2008) analyzed cardiac toxicity in 44 lapatinib 
trials, involving 3689 patients. Lapatinib was administered 
as monotherapy or in combination with chemotherapy in 
these studies. Overall, 60 patients (2%) had a cardiac event, 
of which 7 were symptomatic. The mean time of onset of 
these events was 13 ± 9 weeks (95% CI, 2–54 weeks). The 
mean decrease in left ventricular ejection fraction (LVEF) 
was 18.8% ± 5.2% (95% CI, 11%–32%). Fifty-eight per-
cent of the patients had a full (n = 19) or partial (n = 16) 
recovery. No predictive factors of LVEF decrease were 
identiﬁ  ed. Many of the patients studied had prior or concur-
rent treatment including other cardiotoxic drugs such as 
anthracyclines and trastuzumab. However, the overall rate 
of cardiotoxicity reported is low and compares favorably 
with rates reported with trastuzumab (3%–27%) (Seidman 
et al 2002). In relation to the safety of combined lapatinib 
and trastuzumab, preliminary safety data from a phase IIb 
study of pre-operative lapatinib combined with trastuzumab 
and chemotherapy has recently been reported (Guarneri et al 
2008). No signiﬁ  cant cardiac toxicities have been reported 
after 24 weeks in the ﬁ  rst 20 evaluable patients.
The precise reasons for the higher rate of cardiotoxicity 
with trastuzumab compared to lapatinib are not entirely 
clear. Inhibition of HER-2 signaling by trastuzumab may 
cause cardiomyocyte dysfunction (Grazette et al 2004); 
however, this does not appear to be the case with lapatinib 
(Geyer et al 2006). Although lapatinib and trastuzumab 
both target HER-2, it has been proposed that these drugs 
have different mechanisms of action. Spector et al (2007) 
have shown that GW2974 (a dual EGFR/HER-2 small 
molecule inhibitor which is similar to lapatinib) initiates 
a stress response via AMP-activated protein kinase which 
protects against TNFα-mediated cell death in human 
cardiomyocytes. In contrast, trastuzumab does not activate 
this key metabolic pathway, and is not cardio-protective in 
the same way (Spector et al 2007). A proposed differential 
mechanism of action of trastuzumab relates to the key 
signaling protein BCL-antagonist of death (BAD). Inhibi-
tion of HER-2 reverses BAD inhibition, which plays a role 
in mitochondrial function and apoptosis in breast cancer. 
In normal cardiomyocytes, HER-2 antibody-mediated 
modulation of BAD (which alters the ratio of BCL-XS (pro-
apoptotic):BCl-XL (anti-apoptotic)), may cause mitochondrial 
depolarization, depletion of ATP and contractile dysfunction 
(Grazette et al 2004). It has been suggested that this is an 
unique response to antibody binding and may explain the 
increased cardiotoxicity associated with trastuzumab (Force 
et al 2007). Monitoring of potential cardiotoxicity is ongoing 
in trials of lapatinib.
Rash
Skin rash is a common adverse event associated with 
lapatinib use. This appears to be a class effect of drugs which 
inhibit EGFR, including geﬁ  tinib and erlotinib, and may be 
mediated by EGFR inhibition in the epidermis (Gordon et al 
2005; Cersosimo 2006; Geyer et al 2006; Lacouture 2006). 
A recent review analyzed adverse skin events in 1419 patients 
Table 2 Phase I studies with lapatinib (GW572016)
Study ID (reference) Setting MTD/OTR Cardiac Diarrhea Rash Other
EGF10001 (Bence et al 2005) Healthy 250 mg (single dose) NR 4% 8% Headache (23%)
EGF10003 (Pandite et al 2004) Solid tumors 1800 mg OD NR 17% 9% Nausea (16%)
900 mg BD NR 29% 11% Nausea (11%)
EGF10004 (Burris et al 2005) Metastatic 500–1600 mg OD 1.5%a 42% 31% Fatigue (10%); 
Nausea (13%)
EGF10005 (Chu et al 2007) Solid tumors 1250 mg OD + C 2000 mg/m2/d NR 67% 44% Nausea (49%)
EGF10009 (GlaxoSmithKline) Solid tumors 1500 mg OD + P 175 mg/m2 q3wk 2%b 80%b 73%b Fatigue (75%)b; 
Nausea (73%)b
EGF10021 (GlaxoSmithKline) Solid tumors 1250 mg OD + D 75 mg/m2 q3wk 2%c 71% 54% Nausea (31%)
EGF10023 (Storniolo et al 2008) HER2+ ABC 1000 mg OD + trastuzumab 1.9%d ∼ 90%e ∼ 40% Fatigue (52%)
EGF10030 (GlaxoSmithKline) ER+/PR+ ABC 1500 mg OD + letrozole 2.5 mg 3% 77% 64% Nausea (49%)
NR: not reported; aone patient with asymptomatic LVEF decrease; b adverse side-effects reported are in the group treated with paclitaxel q3wk + lapatinib only; cone patient with 
congestive cardiac failure; done patient with greater than 20% decrease in left ventricular ejection fraction, which subsequently resolved; eestimate from published bar graph;
Abbreviations: MTD, maximum tolerated dose; OTD, optimum tolerated dose; OD, once daily; BD, twice daily; C, capecitabine; P, paclitaxel; D, docetaxel;  ABC, advanced breast 
cancer; ER, estrogen receptor; PR, progesterone receptor; LVEF, left ventricular ejection fraction.OncoTargets and Therapy 2008:1 26
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from 8 lapatinib trials (Sweetman et al 2007). These trials 
included lapatinib monotherapy (n = 928), and lapatinib 
in combination with capecitabine or paclitaxel (n = 491). 
Fifty-two percent of patients treated with lapatinib, and 
73% of patients with combination treatment experienced 
adverse skin events. However, most events were low grade 
(53% grade 1 or 2; 6% grade 3; none grade 4) and treatment 
discontinuation was required in 1% of cases. Most lapatinib 
related events occurred early (within 14 days), and were 
distributed mainly on the trunk, and less frequently on the 
face (Sweetman et al 2007).
Interestingly, the severity of cutaneous side-effects with 
other EGFR inhibitors has been associated with improved 
tumor response (Perez-Soler and Saltz 2005; Moy and Goss 
2007). While this has not been fully explored in relation to 
these drugs, the same may hold true for lapatinib, and may 
be a source of some comfort to those who experience rash 
as result of lapatinib use.
Other adverse events associated 
with lapatinib
Abnormal liver biochemistry and hyperbilirubinemia events 
have been reported in a number of lapatinib clinical studies 
(Bence et al 2005; Chu et al 2007; Siegel-Lakhai et al 2007). 
An incidence of 0.4% hepatotoxicity in the entire lapatinib 
clinical trials program has been reported (http://www.gsk.
com/media/pressreleases/2008/2008_pressrelease_10019.
htm). These have been predominantly elevations in liver 
enzymes. In most cases patients have recovered once 
lapatinib has been discontinued. One case of hepatic failure 
related to lapatinib was reported in EGF20009 (n = 138), a 
ﬁ  rst-line monotherapy phase II study (Gomez et al 2008). 
GlaxoSmithKline has recommended increased frequency of 
serum liver biochemistry monitoring.
Clinical studies have reported cases of interstitial 
pneumonitis with other EGFR inhibitors including geﬁ  tinib 
(Konishi et al 2005; Sunaga et al 2007). No interstitial 
pneumonitis occurred in the lapatinib phase I study 
(EGF10004). There was one case of pulmonary metasta-
ses where fatal interstitial pneumonia developed, which 
was determined to be related to the underlying disease 
(Burris et al 2005). There was also one case of pneumonitis 
(1/52) with the safety and tolerability study of lapatinib 
and docetaxel (EGF10021). This occurred at the highest 
dose used (lapatinib 1500 mg/docetaxel 75 mg/m2 q3wk) 
(GlaxoSmithKline). The overall incidence of pneumonitis 
with lapatinib treatment appears to be very low.
Quality of life issues
In general, lapatinib is a well tolerated drug in monotherapy 
(Burris et al 2005). The most noteworthy side-effects are 
those listed above, and are generally of low grade.
In the combination study of lapatinib and FOLFOX4 
chemotherapy (EGF10010), 10 of the 34 patients went off 
study as a result of drug-related adverse events, including 
diarrhea, fatigue, elevated serum bilirubin, weight loss, 
decreased LVEF, fatigue, hypersensitivity, and thrombocy-
topenia (Siegel-Lakhai et al 2007). Diarrhea was a signiﬁ  cant 
problem on this study, and this may have been due in part to 
the chemotherapy regimen.
Formal quality of life (QoL) assessment has recently been 
presented in relation to EGF100051, the pivotal phase III 
trial of combined lapatinib and capecitabine treatment in 
HER-2 positive metastatic breast cancer (Zhou et al 2008). 
The study aimed to assess clinically important differences 
between the group receiving the combination (n = 198) and 
capecitabine alone (n = 201). Outcome measures included 
quality of life measures (including the Functional Assessment 
of Cancer Therapy-Breast (FACT-B) total, FACT-general 
(FACT-G), trial outcome index (TOI), EQ-5D utility, and 
EQ-5D visual analogue scale (VAS), and percentage tumor 
response. Although the result was not statistically signiﬁ  cant, 
a greater proportion of patients receiving the combined 
treatment achieved a clinically important difference for all 
QoL questionnaires. Also, there was a positive correlation 
between higher QoL scores and tumor response in the 
combination arm, compared to capecitabine alone (p = 0.02 
to 0.07). These data suggest that lapatinib and capecitabine 
is a regimen that has clinical beneﬁ  t and a positive impact 
on patients’ quality of life.
Lapatinib efﬁ  cacy studies
Lapatinib as monotherapy
The efﬁ  cacy of single agent lapatinib as second-line therapy 
in advanced/metastatic breast cancer has been studied in a 
number of trials (Table 3). An open-label single arm phase II 
study in patients with advanced or metastatic HER-2 positive 
breast cancer that had progressed on prior trastuzumab-
containing regimens (EGF20002) showed an overall response 
rate of 5.1% (4/78) (GlaxoSmithKline). A phase II study 
(EGF20008) examined the safety and efﬁ  cacy of lapatinib 
monotherapy in chemotherapy-refractory tumors (Burstein 
et al 2008). This study included 2 cohorts of patients, HER-2 
positive (Cohort A, n = 140) and HER-2 negative (Cohort B, 
n = 89). More than 95% of patients had stage IV disease, and OncoTargets and Therapy 2008:1 27
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nearly all patients had received 3 or more lines of anti-cancer 
therapy previously. Ninety-seven percent of HER-2 positive 
patients had received at least 12 weeks of prior trastuzumab 
therapy. Lapatinib 1500 mg daily was administered, with 
dose reduction to 1250 mg in the event of grade 3/4 toxicity. 
The best response was observed in the HER-2 positive cohort. 
There was an overall response rate of 1.4% (0.2%–5.1%) 
in the HER-2 positive cohort and 0.0% (0.0%–4.1%) in the 
HER-2 negative cohort. The independent review reported that 
5.7% of HER-2 positive patients received a clinical beneﬁ  t 
(CB), but there was no CB in the HER-2 negative group. 
Median overall survival was 29.4 weeks (cohort A) versus 
18.6 weeks (cohort B). These responses were modest, but 
this was a heavily pretreated cohort. A similar phase II study 
of lapatinib monotherapy (1500 mg daily) in 67 Japanese 
patients with refractory positive advanced/metastatic breast 
cancer (EGF100642) demonstrated a much greater beneﬁ  t 
in the HER-2 positive subgroup (response rate 24% vs 5%) 
(Toi et al 2007). While the trend for beneﬁ  t in the HER-2 
positive cohorts in these studies is the same, the reasons for 
a greater response rate in the Japanese study are unclear.
A phase II open-label, two stage, study of lapatinib 
monotherapy in patients with inﬂ  ammatory breast cancer 
(IBC) has also been initiated (EGF103009). IBC is a par-
ticularly aggressive form of breast cancer, and is associated 
with a poor prognosis (Chang et al 1998). Initially, patients 
were recruited in two cohorts of IBC (A) HER-2 positive 
(n = 32) and (B) EGFR positive/HER-2 negative (n = 15), 
which had progressed on prior chemotherapy or trastuzumab. 
The patients were treated with lapatinib (1500 mg daily) 
and response was measured by RECIST and skin biopsies. 
A 50% response rate was observed in the initial cohort of 
HER-2 positive patients, and this cohort was expanded to 
include 126 patients. There was one partial response (PR) 
among the 15 patients in the EGFR positive/HER-2 nega-
tive cohort, and enrolment in this arm was closed (Johnston 
et al 2008; Kaufman et al 2008). Preliminary analysis of 
the expanded HER-2 positive arm shows an approximately 
40% response rate, and subgroup analysis of trastuzumab-
refractory tumors shows an approximately 50% response 
(Kaufman et al 2008). These results suggest that lapatinib 
monotherapy is active in the treatment of relapsed/refractory 
HER-2 positive IBC.
A phase II study (EGF20009) assessed the clinical activity 
and safety of lapatinib as a ﬁ  rst line treatment in locally 
advanced or metastatic HER-2 positive breast cancer without 
prior HER-2-targeted therapy. The overall response rate was 
24% (n = 138) and did not differ signiﬁ  cantly between the 
two dosage groups (1500 mg daily or 500 mg twice daily). 
The median duration of response was 28.4 weeks, and 
progression free survival was 63% at 4 months, and 43% at 
6 months (Gomez et al 2008). This trial suggests a role for 
ﬁ  rst-line lapatinib therapy in locally advanced or metastatic 
HER-2 positive breast cancer.
It has been noted that patients with trastuzumab-treated 
HER-2 positive breast cancer tend to have a higher incidence 
Table 3 Phase II trials with lapatinib (GW572016) monotherapy in advanced/metastatic breast cancer
Study ID (reference) Lapatinib dose Population n Response rate
EGF20002 (GlaxoSmithKline) 1250 mg, amended to 
1500 mg
T-refractory ABC/MBC 78 5.1%
EGF105084a (Lin et al 2008a) 750 mg BD T-refractory/relapsed HER-2+ 
with brain metastases
39 2.6%
EGF103009 (Kaufman et al 2008) 1500 mg OD Chemo-/T-refractory/relapsed 
IBC, HER-2+ (n = 126); 
EGFR+/HER-2– (n = 15)
141 HER-2+: 40%b
EGFR+/HER-2–: 1 PR
EGF100642 (Toi et al 2007) 1500 mg OD Chemo-/T-refractory 
LABC/MBC, HER-2+ (n = 45), 
HER-2- (n = 22)
67 HER-2+: 24% (0 CR, 11 PR)
HER-2–: 5% (1 CR, 0 PR)
EGF20008 (Burstein et al 2008) 1500 mg OD Chemo-refractory ABC/MBC 229 HER-2+: 4.3%; HER-2–: 0.0%c
EGF20009 (Gomez et al 2008) 1500 mg OD or 500 mg BD First-line HER-2+ LABC/MBC 138 24%
aAn extension arm in EGF105084 with lapatinib 1250 mg OD + capecitabine 2000 mg/m2/day is ongoing; bestimated response rate based on preliminary data; cby independent 
review.
Abbreviations: RR, response rate; ORR, overall response rate; OD, once daily; BD, twice daily; T, trastuzumab; Chemo, chemotherapy; LABC, locally advanced breast cancer; 
MBC, metastatic breast cancer; IBC, inﬂ  ammatory breast cancer; PR, partial response; CR, complete response.OncoTargets and Therapy 2008:1 28
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of CNS relapse (Bendell et al 2003). This may in part be 
due to the limited ability of trastuzumab to cross the BBB 
(Pestalozzi and Brignoli 2000). In EGF20009, 6 patients 
with stable CNS disease involvement were enrolled. One 
patient had CNS relapse only, 3 patients had systemic 
relapse only, 1 patient died before objective assessment, 
and 1 remained relapse free at the time of discontinuation of 
treatment. In theory, lapatinib has a greater ability to cross 
the BBB, although pharmacokinetic studies have shown 
low CNS levels of the drug in normal healthy animals (Polli 
et al 2008).
EGF105084 speciﬁ  cally studied the use of lapatinib 
monotherapy (750 mg twice daily) for brain metastases 
in HER-2 positive breast cancer with prior trastuzumab 
therapy (n = 39). Preliminary results of this phase II trial 
have reported an overall CNS response rate of 2.6% (1 PR), 
6 patients with stable disease (15.4%) and 7 patients with 
progression free survival (18%) at 16 weeks (Lin et al 2008a). 
There were 4 non-CNS PRs. An association between tumor 
volume reduction, and physician-reported neurological 
signs and symptoms has also been observed (Lin et al 
2008b). An extension arm to EGF105084 for patients with 
progression of disease allowed the patients to be offered 
lapatinib 1250 mg daily + capecitabine 2000 mg/m2/day. 
Of the 40 patients enrolled to this arm (as of March 2007), 
20% had 50% tumor volume reduction (median absolute 
reduction 6.2 cm3), and 40% had 20% reduction (median 
3.9 cm3) (Lin et al 2007). These early data suggest that 
the combination of lapatinib and capecitabine may be of 
beneﬁ  t in patients whose CNS disease has progressed on 
monotherapy with lapatinib.
Lapatinib in combination 
with chemotherapy
The combination of a lapatinib analogue (GW282974X) 
with the capecitabine metabolite 5’-deoxy-5-ﬂ  uorouridine 
was synergistic in vitro in breast cancer cell lines (Budman 
et al 2006). A phase I study (EGF10005) found the optimal 
tolerated regimen for the combination to be 1250 mg 
lapatinib daily and 2000 mg/m2/day capecitabine on days 
1 to 14 of a 21-day cycle. Four conﬁ  rmed responses from 
45 patients were reported, including 2 breast malignancies 
(1 complete response and 1 partial response) (Chu et al 2007). 
The complete response occurred in a patient that had disease 
progression while receiving trastuzumab.
An open-label phase III randomized clinical trial 
(EGF100151) proceeded on the basis of these encouraging 
data. A total of 399 patients with locally advanced or 
metastatic HER-2 positive breast cancer who had progressed 
after treatments including trastuzumab, anthracyclines, 
and taxanes were randomized to receive the combination 
of lapatinib and capecitabine versus capecitabine alone 
(Table 4). The primary study endpoint was time to disease 
progression (TTP). An interim analysis was reported in 2006 
with 324 patients (Geyer et al 2006), which showed a sig-
niﬁ  cantly reduced TTP in the combination arm (median 8.4 
months vs 4.4 months in the monotherapy arm; hazard ratio 
[HR] 0.49; 95% CI 0.34 – 0.71; p  0.001). A reduction in 
the number of patients who developed CNS disease in the 
combination arm in comparison to the monotherapy arm was 
also reported, although the difference was not signiﬁ  cant. As 
a result of the increased beneﬁ  t with the combination therapy, 
accrual was discontinued, and cross-over was offered to those 
on the monotherapy arm. Seventy-ﬁ  ve more patients were 
included in the updated analyses which have recently been 
published (Cameron et al 2008). TTP remains highly signiﬁ  -
cant (6.2 months vs 4.3 months; HR 0.57 (95% CI, 0.43–0.77; 
p  0.001). There has been 1 complete response (CR) ( 1%) 
in the combination arm, vs 0 (0%) in the monotherapy arm. 
The odds ratio for overall response was 1.9, (95% CI, 1.1–3.4, 
p = 0.017). The decreased incidence of CNS metastases with 
lapatinib therapy was statistically signiﬁ  cant in this analysis 
(p = 0.045). These data strongly suggest a beneﬁ  t for the 
combination of lapatinib and capecitabine over capecitabine 
alone in patients with advanced or metastatic HER-2 posi-
tive breast cancer that have progressed on other treatments. 
Lapatinib, combined with capecitabine, has been licensed for 
use in the US in refractory HER-2 positive metastatic breast 
cancer on the basis of the EGF100151 data.
Taxane-based chemotherapy has been a mainstay of 
breast cancer treatment in the adjuvant and metastatic 
settings for a generation. The efficacy and safety of 
lapatinib and 3-weekly paclitaxel was established in a phase 
I study (EGF10009) (Jones et al 2004). The combination 
of lapatinib and weekly paclitaxel has shown efﬁ  cacy in 
the phase II neoadjuvant setting for inﬂ  ammatory breast 
cancer (EGF102580), with a response rate of 78.6% in the 
HER-2 positive subgroup (GlaxoSmithKline) (Table 4). 
A phase III, randomized study examined lapatinib combined 
with paclitaxel as ﬁ  rst-line treatment for metastatic breast 
cancer, which was either HER-2 negative or has never been 
tested, (EGF30001) (Di Leo et al 2007) (Table 4). In this 
double-blind study, 579 patients were randomized to receive 
paclitaxel (175 mg/m2) and either lapatinib (1500 mg daily; 
n = 293) or placebo (n = 286). The primary endpoint was to 
achieve a 40% increase in median TTP in the intention-to-treat OncoTargets and Therapy 2008:1 29
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population. Patient characteristics were well balanced 
between both groups. The overall response rate (35.1% vs 
25.3%) was signiﬁ  cant (odds ratio [OR] 1.7, p = 0.008). 
The clinical beneﬁ  t rate was 40.5% versus 31.9% (OR = 1.5, 
p = 0.025). There was no signiﬁ  cant difference between the 
two arms in TTP, or overall survival (Di Leo et al 2007). 
However, signiﬁ  cant differences emerged in the HER-2 
positive and negative subgroup analyses. Of the samples 
tested in the combination arm (n = 291), 19% were HER-2 
positive and 74% were HER-2 negative. The results were 
similar in the placebo arm (n = 288) (15% HER-2 positive vs 
77% HER-2 negative). Importantly, there was a greater 
response rate in the HER-2 positive subpopulation in the 
combination arm of 60% versus 36% in the placebo arm 
(OR 2.9, p = 0.027). This contrasts with a non-signiﬁ  cant 
increased response in the HER-2 negative patients (31% vs 
24%, OR = 1.5, p = 0.118). The median duration of response 
was longer with the combination for the HER-2 positive 
patients (7.4 vs 5.5 months), while the median duration of 
response was less in the combination arm in HER-2 negative 
patients compared with paclitaxel alone (6.2 vs 8.5 months). 
A signiﬁ  cant TTP was also seen in HER-2 positive patients 
(median 8.1 vs 5.8 months, p = 0.011). The interaction 
between HER-2 status and the combination treatment was 
signiﬁ  cant by Cox’s proportional hazards model (p = 0.032). 
Similar results were found for event free survival. The 
addition of lapatinib to paclitaxel appears to be of beneﬁ  t in 
certain breast cancer subpopulations, eg, HER-2 positive. 
Analysis is ongoing to reﬁ  ne this observation, eg, correla-
tion of EGFR status and response. Two trials testing weekly 
paclitaxel and lapatinib in HER-2 positive advanced breast 
cancer are also underway (EGF104535, EGF105764). These 
will provide further efﬁ  cacy data, and explore safety and 
tolerability issues raised by this study. A large phase III 
study comparing lapatinib or trastuzumab with taxanes is 
also planned (EGF108919).
The results of the phase II and this phase III trial, which 
included both HER-2 positive and HER-2 negative tumors, 
have shown efﬁ  cacy of lapatinib in HER-2 positive breast 
cancer populations but no signiﬁ  cant beneﬁ  t in HER-2 nega-
tive patients. As a result the current focus of research for this 
drug is in HER-2 positive, rather than in HER-2 negative 
(EGFR positive) breast cancer.
Lapatinib in combination with hormone 
therapy
In an in vitro model of acquired resistance to lapatinib, 
acquired resistance was attributed to a switch in cell 
survival dependence from HER-2 alone to co-dependence 
upon ER and HER-2 (Xia et al 2006). Short-term exposure 
(14 days) to lapatinib also increased ER signaling in breast 
cancer patients. These findings provided the rationale 
for developing clinical trials of hormone therapies with 
lapatinib in HER-2 positive, ER positive breast cancer. 
There is also evidence that lapatinib can overcome hormone 
resistance, caused by cross-talk between HER-2 and ER, in 
preclinical models (Chu et al 2005). A phase III study of 
lapatinib combined with letrozole versus letrozole alone in 
post-menopausal women with estrogen-receptor positive 
metastatic breast cancer is currently ongoing. Patients are 
randomized to letrozole with or without lapatinib regardless 
of HER-2 status to test that hypothesis that lapatinib treat-
ment may prevent the conversion of ER positive/HER-2 
negative to ER positive/HER-2 positive breast cancer, thus 
blocking the development of resistance to endocrine therapy 
(Chowdhury et al 2007). Two phase II trials in hormone-
resistant, ER positive metastatic breast cancer are currently 
examining lapatinib as single agent (NCT00225758) or in 
combination with tamoxifen (NCT00118157).
Lapatinib as neoadjuvant therapy
The potential role of lapatinib as neoadjuvant therapy in 
HER-2 positive locally advanced breast cancer is currently 
being evaluated. A phase II study reported promising results 
for the combination of lapatinib and paclitaxel as neoad-
juvant therapy in newly diagnosed inﬂ  ammatory breast 
cancer (EGF102580). The combined clinical response rate 
was 78.6% in the HER-2 positive cohort and 71.4% in the 
HER-2 negative/EGFR positive cohort (GlaxoSmithKline). 
These preliminary data suggest potential activity of the 
combination in these populations. A phase II study with lapa-
tinib monotherapy is currently recruiting (www.clinicaltrials.
gov, NCT00206427) and a phase I/II study of lapatinib and 
docetaxel with or without combination chemotherapy is 
underway (EORTC-10054).
Lapatinib in combination with other 
targeted agents
The safety and efﬁ  cacy of lapatinib as monotherapy and in 
combination with chemotherapy is being recognized. Novel 
approaches of dual HER-2 targeting, and of combining lapa-
tinib with anti-vascular agents are being investigated.
The combination of lapatinib and trastuzumab enhances 
apoptosis in HER-2 over-expressing breast cancer cell lines 
(Xia et al 2005). The optimal tolerated dose of lapatinib and 
trastuzumab, a monoclonal antibody against HER-2, was OncoTargets and Therapy 2008:1 30
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determined in a phase I study (EGF10023) (Storniolo et al 
2008). Interestingly, in this population of heavily pretreated 
HER-2 positive advanced breast cancers, there was a 
16% overall response rate. Consequently, there has been a 
phase III trial (EGF104900), comparing the effect of lapatinib 
(1500 mg) alone to the combination of lapatinib (1000 mg) 
and trastuzumab, in metastatic HER-2 positive breast cancer 
which has progressed on prior anthracyclines, taxanes, and 
trastuzumab therapy (n = 296) (Table 4). The combina-
tion demonstrated signiﬁ  cantly improved progression-free 
survival (12 weeks vs 8.4 weeks, OR 0.77, p = 0.029) and had 
a similar side-effect proﬁ  le compared with lapatinib alone. 
One death was related to cardiac toxicity in the combination 
arm. Asymptomatic decrease in left ventricular ejection 
fraction was also more common in the combination arm 
(5% vs 2%). In summary, the data show that combined HER-2 
targeting showed better clinical outcomes in comparison with 
lapatinib alone, in the pretreated metastatic setting, with a 
similar side-effect proﬁ  le (O'Shaughnessy et al 2008).
Ongoing trials involving lapatinib and trastuzumab 
include a phase III trial comparing paclitaxel and trastu-
zumab with lapatinib or placebo in HER-2 positive 
metastatic breast cancer (EGF104383), and a phase I study 
combining lapatinib, trastuzumab, carboplatin and paclitaxel 
(EGF103892).
Bevacizumab is a monoclonal antibody against VEGF, 
and has shown promising activity in combination with trastu-
zumab in preclinical models (Emlet et al 2007). However, 
the cardiac toxicity proﬁ  le of this combination has not 
been established. HER-2 inhibition with lapatinib may be 
a less cardiotoxic alternative. A phase II single arm trial 
is evaluating the combination of lapatinib (1500 mg daily) 
and bevacizumab (10 mg/kg iv q2wk) in 50 patients with 
HER-2 positive metastatic breast cancer. Preliminary data 
report a 12 week progression-free survival of 62% in 16 of 
21 patients evaluated (3 partial response, 10 stable disease, 
3 progressive disease), and the combination is well tolerated 
(Rugo et al 2008).
A phase II evaluation of lapatinib combined with 
the anti-angiogenic tyrosine kinase inhibitor pazopanib, 
versus lapatinib alone (VEG20007) is ongoing in patients 
who have not received prior treatment for their progres-
sive disease. Preliminary reports show a 44% versus 
30% response rate for the combination arm, with a 
73% versus 43% reduction in target lesions at 12 weeks 
(Slamon et al 2008).
Biomarkers of response to lapatinib
Similar to trastuzumab treatment, overexpression of HER-2 
appears to be the most reliable predictive marker of response 
to lapatinib in breast cancer. Within the HER-2 positive breast 
cancer population additional biomarkers will be needed to 
further deﬁ  ne the patients who are likely to beneﬁ  t from 
lapatinib treatment.
Biomarkers of response to lapatinib monotherapy were 
investigated in the phase I study EGF10004 (Spector et al 
2005). Although the numbers were limited, clinical response 
was associated with increased pretreatment expression of 
HER-2, p-HER-2, Erk1/2, p-Erk1/2, insulin-like growth 
factor receptor-1, p70 S6 kinase, and transforming growth 
Table 4 Completed phase II/III combination trials with lapatinib (GW572016) for advanced/metastatic breast cancer
Study ID (reference) Regimen Population Phase n Outcome
EGF102580a
(GlaxoSmithKline)
L 1500 mg OD x 14 days 
→ L 1500 mg + P 80 
mg/m2/wk x 12 weeks
A: HER-2+ ± EGFR+ 
(IBC)
B: HER-2–/EGFR + (IBC)
II 42
7
A: RR 78.6% (95% CI, 63.2–89.7)
B: RR 71.4% (95% CI, 29.0–96.3)
EGF30001 (Di Leo et al 
2007)
P 175 mg/m2 q3wk + 
L 1500 mg OD, or P + 
placebo
MBC HER-2– or 
untested
III 570 TTP: overall no difference, 
signiﬁ  cant in HER2+ subpopula-
tion only (see text)
EGF100151 (Cameron 
et al 2008)
L 1250 mg OD + 
C 2000 mg/m2 vs 
C 2500 mg/m2
LABC/MBC HER-2+ III 399 TTP: HR 0.57 (95% CI, 0.43–0.77, 
p = 0.00013)
OS: HR 0.78 (95% CI, 0.55–1.12, 
p = 0.177)
EGF104900 
(O’Shaughnessy et al 
2008)




III 296 PFS: HR 0.77 (95% CI, 0.6–1.0, 
p = 0.029)
OS (median): HR 0.75 (95% CI, 
0.5–1.1, p = 0.106)
aneoadjuvant study.
Abbreviations: OD, once daily; RR, response rate; TTP, time to progression; OS, overall survival; PFS, progression-free survival;   T, trastuzumab; LABC, locally advanced breast 
cancer; MBC, metastatic breast cancer; IBC, inﬂ  ammatory breast cancer; PR, partial response; CR, complete response.OncoTargets and Therapy 2008:1 31
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factor alpha compared with non-responders. Baseline EGFR 
expression did not correlate with response. HER-2 over-
expression predicted response to lapatinib in the monotherapy 
phase II study EGF20009 (Gomez et al 2007), the phase 
I lapatinib/capecitabine study EGF100151 (Cameron et al 
2008), and the phase III lapatinib/paclitaxel study EGF30001 
(Press et al 2008). Press et al (2008) also reported than the 
beneﬁ  t from lapatinib in HER-2 positive metastatic breast 
cancer may be limited to patients with FISH positive or 
immunohistochemical 3+ staining intensity.
The extracellular domain (ECD) of HER-2 is cleaved 
by ADAM protease enzymes (Liu et al 2006) and can 
readily be detected in the serum of HER-2 positive breast 
cancer patients. After cleavage of the ECD, the remaining 
p95 form of HER-2 retains kinase activity. This form of 
HER-2 has been associated with resistance to trastuzumab 
treatment but is inhibited by lapatinib (Scaltriti et al 2007). 
Increased pre-treatment levels of serum HER-2 ECD 
correlate positively with response to lapatinib, and decreas-
ing levels during treatment are associated with clinical 
beneﬁ  t in HER-2 positive metastatic breast cancer (Lipton 
et al 2007). However, response to lapatinib appeared to be 
independent of baseline HER-2 ECD levels in the pivotal 
phase III capecitabine/lapatinib trial (EGF100151) (Cameron 
et al 2008). High baseline levels of HER-2 ECD in HER-2 
negative metastatic breast cancer did not predict response 
to lapatinib and paclitaxel or paclitaxel alone (Finn et al 
2008). Neither EGFR expression nor baseline EGFR ECD 
levels affected progression free survival in the capecitabine/
lapatinib trial (EGF100151) (Cameron et al 2008).
In the phase I monotherapy study EGF10004, inhibition 
of phosphorylated AKT and MAPK (downstream targets 
of HER-2 and EGFR) at day 21 were also associated with 
clinical responses (Spector et al 2005). Loss of PTEN 
expression (a negative regulator of AKT), which has been 
associated with resistance to trastuzumab treatment does 
not appear to preclude response to lapatinib in patients with 
inﬂ  ammatory breast cancer (Xia et al 2007). Phosphorylation 
of p70 S6 kinase, a downstream target of mTOR (mammalian 
target of rapamycin), has also been reported as a potential 
biomarker for lapatinib activity in human breast cancer cell 
lines (Vazquez-Martin et al 2008).
Forkhead box group O transcriptional factor (FoxO3A) 
is a downstream target of the PI3 kinase pathway, which 
regulates cell proliferation, survival, and malignant trans-
formation. FoxO3A has previously been shown as a direct 
target of EGFR inhibitors, including lapatinib, in two 
sensitive HER-2 positive breast cancer cell lines, BT474 and 
SKBR3 (Krol et al 2007). Gene array data from EGF100151 
suggested that elevated baseline FoxO3A mRNA levels 
and reduced BCL-2 mRNA correlated with response to 
the combination of lapatinib and capecitabine (Crown 
et al 2007).
Conclusions
Although lapatinib is a dual inhibitor of EGFR and HER-2, it 
is clearly evident from trials including both HER-2 positive 
and HER-2 negative breast cancer patients, that the beneﬁ  ts 
of lapatinib treatment are largely restricted to HER-2 positive 
breast cancer. Lapatinib has shown activity in trastuzumab-
refractory HER-2 positive breast cancer and at present is 
approved, in combination with capecitabine, for treatment of 
refractory HER-2 positive metastatic breast cancer. Recent 
trial results suggest that combined trastuzumab and lapatinib 
treatment show greater efﬁ  cacy than lapatinib alone in 
trastuzumab-refractory metastatic breast cancer. Lapatinib 
has also shown promising activity as ﬁ  rst-line treatment 
for HER-2 positive metastatic breast cancer and the results 
of ongoing phase III trials will help to deﬁ  ne the role of 
lapatinib in this setting. Lapatinib may also have a speciﬁ  c 
role for treatment HER-2 positive breast cancer patients with 
CNS metastases. Due to the apparent lack of cardiotoxicity, 
lapatinib may also have beneﬁ  ts in combination therapy with 
anthracyclines. A phase I study of lapatinib with epirubicin is 
currently underway to determine the safe dose of epirubicin 
in combination with lapatinib and to examine the cardiotox-
icity of this combination. Several large randomized clinical 
trials are also underway at present to evaluate the beneﬁ  ts of 
lapatinib treatment for early stage breast cancer.
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